PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. (Q50773167)

19 March 2018

title

PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. (English)

1 reference

19 March 2018

0 references

1 reference

4

1 reference

19 March 2018

author name string

Anna C Calkin

1

1 reference

19 March 2018

Sara Giunti

2

1 reference

19 March 2018

Karin A Jandeleit-Dahm

3

1 reference

19 March 2018

Mark E Cooper

5

1 reference

19 March 2018

Merlin C Thomas

6

1 reference

19 March 2018

language of work or name

English

0 references

publication date

23 May 2006

1 reference

19 March 2018

Nephrology Dialysis Transplantation

published in

1 reference

19 March 2018

volume

21

1 reference

19 March 2018

issue

9

1 reference

19 March 2018

page(s)

2399-2405

1 reference

19 March 2018

Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Rosiglitazone Activates Renal Sodium- and Water-Reabsorptive Pathways and Lowers Blood Pressure in Normal Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

PPARα ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Bezafibrate suppresses rat antiglomerular basement membrane crescentic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Decreased longevity and enhancement of age-dependent lesions in mice lacking the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-indepen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFL212

21 January 2018

Identifiers

DOI

10.1093/NDT/GFL212

1 reference

19 March 2018

1 reference

19 March 2018